Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
The study marks victory against Soliris, but Apellis could still find the market hard to crack.
Biomarin awaits pivotal data on one of its growth drivers, while Apellis seeks to take off on Pegasus.
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Achillion’s pivot to a next-gen project in paroxysmal nocturnal haemoglobinuria is an admission that its first attempt to compete with Alexion’s Soliris has fallen short.
Promising data in myasthenia gravis, plus a pledge to compete on price, means that Ra Pharmaceuticals’ zilucoplan could soon give Alexion a headache – and others are…
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.